An Update of Gonadotropin-Releasing Hormone Antagonists in the Treatment of Advanced Prostate Cancer
Korean Journal of Urological Oncology
;
: 79-91, 2021.
Article
in Korean
| WPRIM
| ID: wpr-894835
ABSTRACT
For decades, androgen deprivation therapy (ADT) was the cornerstone treatment for advanced prostate cancer. ADT using gonadotropin-releasing hormone (GnRH) agonist or antagonist acts by blocking the hypothalamic-pituitary-gonadal system with different mechanism. Both injectable GnRH agonist and antagonist are currently used as a standard of care. The novel oral GnRH antagonist has recently approved and it may have a promising alternative to the conventional ADT. This review will focus on the history of drug development, efficacy and safety profiles for GnRH antagonists in patients with prostate cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Korean
Journal:
Korean Journal of Urological Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS